Investors

Investors
<picture><source type="image/webp" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/18e05/Image-1.webp 740w,/static/2cf241996b0d6d9b54351b76891640b8/81bef/Image-1.webp 1480w,/static/2cf241996b0d6d9b54351b76891640b8/2d0b8/Image-1.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/bbd3f/Image-1.jpg 740w,/static/2cf241996b0d6d9b54351b76891640b8/087e6/Image-1.jpg 1480w,/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg 2960w" alt="&lt;p&gt;Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.&lt;/p&gt;
"/></picture>
Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Overview
Press releases
Events & presentations
Corporate Governance
Articles of Association
General meeting
Board of Directors
Corporate governance reports
Senior executives
Nomination committee
Remuneration and the remuneration committee
Auditors and audit committee
Scientific committee
Scientific advisory board
Archived transactions
Shareholder & stock info
Share monitor
Shareholders
Convertible bonds
Analyst coverage
Financial reports
Financial calendar
Letter from the CEOIn Q3 of 2022, we brought Mendus in a strong position to reach its upcoming milestones. We have been preparing for presentation of the updated survival results from our ADVANCE II Phase 2 trial, which evaluates DCP-001 as a novel immunotherapy in AML. The data will be presented in less than a month from now at ASH, the world’s largest haematology conference. Also at ASH, we will present extensive immunomonitoring data, which have been collected as part of the ADVANCE II trial to deepen our understanding of the effect of DCP-001 on the immune system, residual disease and, most importantly, disease-free and overall survival.
To read the full letter from the CEO, please click here.
Latest Company PresentationView the latest company presentation
 
Mendus KOL Event – November 2022Watch the replay
 
ASH 2022 WebcastWatch the replay
 
Latest press releasesFebruary 2023Regulatory Release
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the...
Learn more
January 2023Regulatory Release
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the...
Learn more
Upcoming EventsJanuary 2023
12th Annual LifeSci Partners Corporate Access Event
Members of Mendus’ leadership team and Business Development team will be in San Francisco during the JPM Annual Healthcare Meeting 2023.
Learn more
December 2022
Webcast – 64th American Society of Hematology Annual Meeting
Updated results from the Phase 2 ADVANCE II clinical trial were presented in an oral presentation on December 12. In addition, the company presented immunomonitoring data in a separate poster presentation on December 10. 

A replay of the webcast held on December 13 is available via the link below.
Learn more

Contact
Telephone+46 (0)8 732 8400
Emailinfo@mendus.com
<picture><source type="image/webp" srcSet="/static/411b7857055b0888002108e1bcc9e280/e64f1/heado.webp 100w,/static/411b7857055b0888002108e1bcc9e280/8b00d/heado.webp 200w,/static/411b7857055b0888002108e1bcc9e280/9c0a1/heado.webp 400w,/static/411b7857055b0888002108e1bcc9e280/88f3e/heado.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/411b7857055b0888002108e1bcc9e280/10998/heado.jpg" srcSet="/static/411b7857055b0888002108e1bcc9e280/93e3f/heado.jpg 100w,/static/411b7857055b0888002108e1bcc9e280/839ae/heado.jpg 200w,/static/411b7857055b0888002108e1bcc9e280/10998/heado.jpg 400w,/static/411b7857055b0888002108e1bcc9e280/a677a/heado.jpg 800w" alt="&lt;p&gt;Image of old buildings by a dock with boats laying in the water in the foreground.&lt;/p&gt;
"/></picture>
Head OfficeVästra Trädgårdsgatan 15

111 53 Stockholm

Sweden
<picture><source type="image/webp" srcSet="/static/99d97027eda87168e92d8d30678ace5b/e64f1/rdo.webp 100w,/static/99d97027eda87168e92d8d30678ace5b/8b00d/rdo.webp 200w,/static/99d97027eda87168e92d8d30678ace5b/9b01d/rdo.webp 400w,/static/99d97027eda87168e92d8d30678ace5b/08dc5/rdo.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/99d97027eda87168e92d8d30678ace5b/fa758/rdo.jpg" srcSet="/static/99d97027eda87168e92d8d30678ace5b/93e3f/rdo.jpg 100w,/static/99d97027eda87168e92d8d30678ace5b/839ae/rdo.jpg 200w,/static/99d97027eda87168e92d8d30678ace5b/fa758/rdo.jpg 400w,/static/99d97027eda87168e92d8d30678ace5b/3f065/rdo.jpg 800w" alt="&lt;p&gt;City image from a walkway, with a church and tall buildings in the background.&lt;/p&gt;
"/></picture>
R&D OfficesEmmy Noetherweg 2K 

2333 BK Leiden

The Netherlands
<picture><source type="image/webp" srcSet="/static/e29ab9df2993f219c72ad7f14f67fc4a/e64f1/go.webp 100w,/static/e29ab9df2993f219c72ad7f14f67fc4a/8b00d/go.webp 200w,/static/e29ab9df2993f219c72ad7f14f67fc4a/9c0a1/go.webp 400w,/static/e29ab9df2993f219c72ad7f14f67fc4a/88f3e/go.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/e29ab9df2993f219c72ad7f14f67fc4a/10998/go.jpg" srcSet="/static/e29ab9df2993f219c72ad7f14f67fc4a/93e3f/go.jpg 100w,/static/e29ab9df2993f219c72ad7f14f67fc4a/839ae/go.jpg 200w,/static/e29ab9df2993f219c72ad7f14f67fc4a/10998/go.jpg 400w,/static/e29ab9df2993f219c72ad7f14f67fc4a/a677a/go.jpg 800w" alt="&lt;p&gt;Overview image of a city, shot in low sunlight from a far distance.&lt;/p&gt;
"/></picture>
Gothenburg OfficeMendus C/O AstraZeneca BioventureHub

Pepparedsleden 1

431 83 Mölndal

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi--1479869476-kihdmQWi3Drt2kD4pB2PQX:before { opacity: 1; background-image: url('/static/a32348a89302674e113dc101e935b7b3/afb86/about-us-mobile.png'); }

News & eventsAt Mendus, we share a strong commitment to improve the lives of people with cancer.
News & Events

Letter from the CEO

Latest Company Presentation

Mendus KOL Event – November 2022

ASH 2022 Webcast

Latest press releases

Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group

Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group

Upcoming Events

12th Annual LifeSci Partners Corporate Access Event

Webcast – 64th American Society of Hematology Annual Meeting

Contact

Telephone

Email

Head Office

R&D Offices

Gothenburg Office

News & events

Keep up to date